rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RFL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Rafael Holdings submits NDA for rare disease drug remibetadex
      Oct 29Investing.comRFL
      Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
      Oct 4Yahoo FinanceRFL
      Rafael Holdings: A Coin Flip With A Second Binary Attached - Hold (NYSE:RFL)
      Oct 1Seeking AlphaRFL
      Why Is Rafael Stock Falling Wednesday? - Rafael Holdings (NYSE:RFL)

      Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.

      Sep 30BenzingaRFL
      Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint

      Rafael Holdings Inc Class B (NYSE:RFL) shares fell 25% in pre-market trading on Wednesday after the company’s Phase 3 TransportNPC trial of Trappsol Cyclo in patients with Niemann-Pick Disease Type C (NPC) failed to meet its primary endpoint. The study enrolled 94 patients and evaluated the change from baseline in the 4-domain NPC Clinical Severity Scale at Week 96.

      Sep 30Yahoo FinanceRFL
      Rafael Holdings stock tumbles 25% as drug trial misses goal
      Sep 30Investing.comRFL
      Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

      Trappsol® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect versus placebo on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale (4DNPCSS) at Week 96 A prespecified analysis in patients receiving background miglustat and/or leucine therapy, representing approximately 83% of the study population, showed a statistically significant effect on the 4DNPCSS Trappsol® Cyclo™ demonstrated a well-tolerated safety and tolera

      Sep 30Yahoo FinanceRFL
      Why is Rafael stock crashing today?
      Sep 30Investing.comRFL

      This is the newest page. Registered accounts read further back.